

For Immediate Release:
December 4, 2014

Media Contact:
Katie Kiley Brown, NCCN
215.690.0238
brown@nccn.org

NCCN Launches 3D Virtual Simulator Learning Platform

The NCCN 3D Virtual Simulator Learning Platform allows users to walk through the continuum of care approach to colorectal cancer in a risk-free environment with increasingly complex clinical presentations.

FORT WASHINGTON, PA — The [National Comprehensive Cancer Network® \(NCCN®\)](#) has launched a [3D Virtual Metastatic Colorectal Cancer \(mCRC\) Simulator Learning Platform](#) as part of the [NCCN Continuing Education Program](#). To develop the 3D Virtual mCRC Simulator Learning platform, NCCN collaborated with Syandus, Inc., a technology company specializing in development of experiential learning platforms for health care professionals and other learners.

“NCCN is pleased to announce the availability of the 3D Learning Simulator,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “This platform is a virtual, three-dimensional, real-world vision that provides participants with an engaging and self-correcting learning atmosphere.”

Based on the [NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\)](#) for Colon and Rectal Cancers, the simulator enables users to virtually work through the continuum of care approach to colorectal cancer in a risk-free environment with increasingly complex clinical presentations, and features new clinical data and emerging agents.

The NCCN 3D Virtual Simulator Platform tracks progress throughout the simulation of scenarios as users walk through the steps of treating virtual patients, providing immediate feedback on clinical choices and providing an opportunity to reflect and revise approaches to treatment. Users who successfully complete eight scenarios will earn a certificate and three (3) continuing education credits. This education is provided at no cost to learners.

Principal faculty for the simulator are the Chair and Vice-Chair of the NCCN Guidelines® Panels for Colon and Rectal Cancers, Al B. Benson, III, MD, FACP, FASCO, Professor of Medicine at Northwestern University Feinberg School of Medicine, and Associate Director for Clinical

NCCN Launches 3D Virtual Simulator Learning Platform

Investigations at the [Robert H. Lurie Comprehensive Cancer Center of Northwestern University](#), and Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research, [UCSF Helen Diller Family Comprehensive Cancer Center](#), respectively.

A virtual learning platform for multiple myeloma is expected to launch in 2015.

For more information about the NCCN 3D Virtual mCRC Simulator Learning Platform, visit [NCCN.org](#).

###

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred and Pamela Buffett Cancer Center at The Nebraska Medical Center, Omaha, NE; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit [NCCN.org](#). Patients and caregivers, visit [NCCN.org/patients](#).

About Syandus Inc.

Syandus is a leader in intelligent simulation learning technology. Focused in medicine and life science, the company creates digital experience-driven learning environments for clinical training, patient engagement, and life science education. Its unique approach combines game technology

NCCN Launches 3D Virtual Simulator Learning Platform

and clinical algorithms to create responsive personalized learning experiences. Syandus collaborates with medical societies, universities, medical schools, and faculty experts to translate complex topics into approachable learning simulations suitable for the target audience.

Syandus' core simulation technology was developed through several Small Business Innovation Research awards from the National Science Foundation. Syandus' proprietary platform consists of simulation technology, app based delivery (mobile, PC, Mac), and comprehensive analytics of user interactions, performance, and outcomes. These core elements are utilized for clinical training (Medical Scenarios SimulatorTM), patient engagement (Virtual ConversationsTM) and life science education (ImmuneQuestTM). For more information visit www.syandus.com.